2023 World Conference on Lung Cancer (Posters)-P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts

P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts - PDF(Slides)

Back to course

Pdf Summary

A study presented at the World Conference on Lung Cancer explored the use of serum metabolomics to determine the survival of immunotherapy in advanced non-small cell lung cancer (NSCLC) patients. The researchers focused on the metabolomic profile as a means of distinguishing long-term survival from short-term survival in NSCLC patients treated with immune checkpoint inhibitors (ICIs).<br /><br />The study included 97 patients with stage IV NSCLC who were treated with anti-PD-1 inhibitors. The patients were divided into two cohorts: cohort 1 consisted of patients treated with monoimmunotherapy as second-line treatment, and cohort 2 consisted of patients treated with combination immunotherapy as first-line treatment. Serum metabolomic profiling was performed, and differential metabolites were identified using UHPLC-Q-TOF MS analysis.<br /><br />The results showed that there were 41 differential metabolites in cohort 1 and 47 in cohort 2. Eight common metabolites in cohort 1 and 11 in cohort 2 were significantly associated with both progression-free survival (PFS) and overall survival (OS). The primary bile acid synthesis pathway was found to be significantly different between the long-term survival and short-term survival groups in both cohorts.<br /><br />The study suggests that peripheral blood metabolomic analysis is critical for identifying metabolic biomarkers and metabolic pathways responsible for the response to ICIs in NSCLC patients. The primary bile acid synthesis pathway may play an important role in determining survival.<br /><br />Overall, this study highlights the potential of serum metabolomics as a noninvasive tool for predicting the efficacy of ICIs and identifying biomarkers for NSCLC patients. Further research is needed to validate these findings and explore the clinical implications of metabolomic profiling in immunotherapy.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

serum metabolomics

survival

immunotherapy

NSCLC

metabolomic profile

anti-PD-1 inhibitors

differential metabolites

progression-free survival

overall survival

metabolic pathways